Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 3:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 673 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Boehringer Ingelheim Clear all
Completed Phase 2 Interventional Results available

6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

NCT00826267
View directory record Official record
Conditions
Breast Neoplasms
Interventions
lapatinib, BIBW 2992, trastuzumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 16, 2026, 3:59 PM EDT
Completed No phase listed Observational Results available

A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT03979807
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Olodaterol/Tiotropium Bromide, Umeclidinium/ Vilanterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
1 Year to 40 Years
Enrollment
11,296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Oct 16, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients

NCT01422876
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
high dose FDC, BI 10773 high dose, high dose FDC placebo, low dose FDC placebo, high dose BI 10773 placebo, low dose FDC, BI 10773 low dose, linagliptin, linagliptin placebo, BI 10773 low dose placebo, low dose BI 10773 placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
112
States / cities
Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Oct 16, 2026, 3:59 PM EDT
Completed Phase 4 Interventional

Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.

NCT00388882
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, ipratropium bromide / albuterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
10
States / cities
Phoenix, Arizona • Lakewood, California • Sepulveda, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 16, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens

NCT01948141
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
nintedanib
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 16, 2026, 3:59 PM EDT
Not listed No phase listed Observational

Safety of Oral Anticoagulants Registry

NCT02745054
View directory record Official record
Conditions
Blood Coagulation
Interventions
mgt of bleeding concerns/complications of oral anticoagulants
Other
Lead sponsor
Hospital Quality Foundation
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
9
States / cities
Birmingham, Alabama • Hartford, Connecticut • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 16, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy

NCT01649297
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, empagliflozin (low dose qd), Empagliflozin (high dose qd), empagliflozin (high dose bid), empagliflozin (low dose bid)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
983 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
39
States / cities
Florence, Alabama • Jonesboro, Arkansas • Lomita, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 16, 2026, 3:59 PM EDT
Completed Phase 3 Interventional

Duloxetine vs Placebo in the Treatment of General Anxiety

NCT00475969
View directory record Official record
Conditions
Anxiety
Interventions
duloxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 21, 2007 · Synced Oct 16, 2026, 3:59 PM EDT
Active, not recruiting Phase 2 Interventional

Xenon MRI and Progressive ILD

NCT05241275
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions
Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 16, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01431274
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterol, tiotropium, olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
2,624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
35
States / cities
Jasper, Alabama • Mobile, Alabama • Boulder, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 16, 2026, 3:59 PM EDT
Completed Not applicable Interventional

TARA Working Prototype Engagement Evaluation: Feasibility Study

NCT04085302
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Digital Behaviour Change Intervention
Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 16, 2026, 3:59 PM EDT
Completed Phase 2 Interventional

A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

NCT00148486
View directory record Official record
Conditions
Parkinson Disease
Interventions
NS 2330
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 80 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
47
States / cities
Peoria, Arizona • Tucson, Arizona • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 16, 2026, 3:59 PM EDT
Recruiting Phase 3 Interventional

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288
View directory record Official record
Conditions
Heart Failure
Interventions
vicadrostat, empagliflozin, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
6,712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
94
States / cities
Mobile, Alabama • Chula Vista, California • Orange, California + 81 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 16, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity

NCT02871635
View directory record Official record
Conditions
Crohn Disease
Interventions
BI 695501, HUMIRA
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
19
States / cities
Jacksonville, Florida • Kissimmee, Florida • Maitland, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 16, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

BI 10773 add-on to Metformin in Patients With Type 2 Diabetes

NCT00749190
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773, placebo, sitagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 79 Years
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
19
States / cities
Chula Vista, California • Mission Viejo, California • Pasadena, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 16, 2026, 3:59 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Transformative Research in Diabetic Nephropathy 2.0

NCT07444203
View directory record Official record
Conditions
Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 16, 2026, 3:59 PM EDT
Completed Phase 3 Interventional

An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia

NCT06067984
View directory record Official record
Conditions
Schizophrenia, Negative Symptoms in Schizophrenia
Interventions
Study App
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 16, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

NCT01019694
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Combivent CFC-MDI, Combivent Respimat 20/100 mcg, Atrovent HFA 42 mcg + Albuterol HFA 200 mcg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
55
States / cities
Jasper, Alabama • Mobile, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Oct 16, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

NCT02795156
View directory record Official record
Conditions
Non-small Cell Lung Carcinoma, Urothelial Carcinoma, Gastrointestinal Carcinoma, Non-colon, Upper Aerodigestive Tract Carcinoma
Interventions
Afatinib, Regorafenib, Cabozantinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
8
States / cities
Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 16, 2026, 3:59 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

NCT02832037
View directory record Official record
Conditions
Schizophrenia
Interventions
BI 425809 dose 1, BI 425809 dose 2, BI 425809 dose 3, BI 425809 dose 4, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
21
States / cities
Garden Grove, California • Lemon Grove, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 16, 2026, 3:59 PM EDT
Completed Phase 3 Interventional Results available

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

NCT01015118
View directory record Official record
Conditions
Ovarian Neoplasms, Peritoneal Neoplasms
Interventions
Placebo, Paclitaxel, BIBF 1120, Carboplatin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
33
States / cities
Tucson, Arizona • Long Beach, California • Santa Rosa, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 16, 2026, 3:59 PM EDT
Completed Phase 1 Interventional

This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)

NCT03449381
View directory record Official record
Conditions
Neoplasms
Interventions
BI 907828
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
9
States / cities
Santa Monica, California • New Haven, Connecticut • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 16, 2026, 3:59 PM EDT
Terminated Phase 3 Interventional Results available

LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

NCT01345669
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Placebo, Afatinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
15
States / cities
Little Rock, Arkansas • Orange, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 16, 2026, 3:59 PM EDT
Completed Phase 4 Interventional Results available

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2

NCT01662986
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
50
States / cities
Montgomery, Alabama • Flagstaff, Arizona • Glendale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 16, 2026, 3:59 PM EDT